Comment from Glacis

Summary: Jennifer Shannon, MD, representing Glacis Technologies, provides specific recommendations for evaluating the trustworthiness of AI in early-phase clinical trials. The commenter argues that trustworthiness should be assessed through a verifiable record of real-time behavior at the input and output boundaries, rather than through internal system access, to protect proprietary information while ensuring safety and auditability.